958 related articles for article (PubMed ID: 20470309)
41. Three-year posttransplant graft survival in renal-transplant patients with graft function at 6 months receiving tacrolimus or cyclosporine microemulsion within a triple-drug regimen.
Irish W; Sherrill B; Brennan DC; Lowell J; Schnitzler M
Transplantation; 2003 Dec; 76(12):1686-90. PubMed ID: 14688516
[TBL] [Abstract][Full Text] [Related]
42. Parental donors in live-donor kidney transplantation associated with increased rejection rates and reduced glomerular filtration rates.
Lim WH; Chang SH; Coates PT; McDonald SP
Transplantation; 2007 Oct; 84(8):972-80. PubMed ID: 17989602
[TBL] [Abstract][Full Text] [Related]
43. Role of human leukocyte antigen, donor-specific antibodies, and their impact in renal transplantation.
Thiyagarajan UM; Bagul A; Frost J; Horsburgh T; Nicholson ML
Transplant Proc; 2012 Jun; 44(5):1231-5. PubMed ID: 22663991
[TBL] [Abstract][Full Text] [Related]
44. Combined introduction of anti-IL2 receptor antibodies, mycophenolic acid and tacrolimus: effect on malignancies after renal transplantation in a single-centre retrospective cohort study.
Braconnier P; Del Marmol V; Broeders N; Kianda M; Massart A; Lemy A; Ghisdal L; Le Moine A; Madhoun P; Racapé J; Abramowicz D; Wissing KM
Nephrol Dial Transplant; 2012 Jun; 27(6):2547-53. PubMed ID: 22123748
[TBL] [Abstract][Full Text] [Related]
45. Human leukocyte antigen mismatches associated with increased risk of rejection, graft failure, and death independent of initial immunosuppression in renal transplant recipients.
Lim WH; Chadban SJ; Clayton P; Budgeon CA; Murray K; Campbell SB; Cohney S; Russ GR; McDonald SP
Clin Transplant; 2012; 26(4):E428-37. PubMed ID: 22672477
[TBL] [Abstract][Full Text] [Related]
46. Primary immunosuppression and outcome differences after heart transplantation: tacrolimus versus cyclosporine.
Castel MA; Farrero M; Vallejos I; Cardona M; Regueiro A; Pérez-Villa F
Transplant Proc; 2011; 43(6):2244-6. PubMed ID: 21839245
[TBL] [Abstract][Full Text] [Related]
47. Late acute humoral rejection in low-risk renal transplant recipients induced with an interleukin-2 receptor antagonist and maintained with standard therapy: preliminary communication.
Morales J; Contreras L; Zehnder C; Pinto V; Elberg M; Araneda S; Herzog C; Calabran L; Aguiló J; Ferrario M; Buckel E; Fierro JA
Transplant Proc; 2011; 43(6):2295-9. PubMed ID: 21839258
[TBL] [Abstract][Full Text] [Related]
48. Alemtuzumab induction and triple maintenance immunotherapy in kidney transplantation from donors after cardiac death.
Schadde E; D'Alessandro AM; Knechtle SJ; Odorico J; Becker Y; Pirsch J; Sollinger H; Fernandez LA
Transpl Int; 2008 Jul; 21(7):625-36. PubMed ID: 18397178
[TBL] [Abstract][Full Text] [Related]
49. Impact of HLA antibodies on graft survival in long-term renal recipients with functional grafts.
Zeng Y; Liu Z; Liu Y; Fan Y; Guo Y; Qiu J
Urol Int; 2014; 92(3):328-33. PubMed ID: 24480999
[TBL] [Abstract][Full Text] [Related]
50. Immunological risk in recipients of kidney transplants from extended criteria donors.
Diet C; Audard V; Roudot-Thoraval F; Matignon M; Lang P; Grimbert P
Nephrol Dial Transplant; 2010 Aug; 25(8):2745-53. PubMed ID: 20220203
[TBL] [Abstract][Full Text] [Related]
51. Preformed donor-specific antibodies and risk of antibody-mediated rejection in repeat renal transplantation.
Tsapepas DS; Vasilescu R; Tanriover B; Coppleson Y; Rekhtman Y; Hardy MA; Dube G; Crew RJ; Ratner LE; Cohen DJ; Mohan S
Transplantation; 2014 Mar; 97(6):642-7. PubMed ID: 24637863
[TBL] [Abstract][Full Text] [Related]
52. Kidneys from older living donors provide excellent intermediate-term outcomes after transplantation.
Balachandran VP; Aull MJ; Charlton M; Afaneh C; Serur D; Leeser DB; Del Pizzo J; Kapur S
Transplantation; 2012 Sep; 94(5):499-505. PubMed ID: 22892992
[TBL] [Abstract][Full Text] [Related]
53. Clinical significance of post kidney transplant de novo DSA in otherwise stable grafts.
Cooper JE; Gralla J; Chan L; Wiseman AC
Clin Transpl; 2011; ():359-64. PubMed ID: 22755431
[TBL] [Abstract][Full Text] [Related]
54. Impact of antibodies against human leukocyte antigens on long-term outcome in pediatric heart transplant patients: an analysis of the United Network for Organ Sharing database.
Rossano JW; Morales DL; Zafar F; Denfield SW; Kim JJ; Jefferies JL; Dreyer WJ
J Thorac Cardiovasc Surg; 2010 Sep; 140(3):694-9, 699.e1-2. PubMed ID: 20537356
[TBL] [Abstract][Full Text] [Related]
55. Spousal versus living unrelated renal transplantation: a retrospective analysis of allograft outcomes.
Solak I; Sezer TO; Toz H; Tatar E; Isayev C; Firat O; Hoscoskun C
Transplant Proc; 2012; 44(6):1710-2. PubMed ID: 22841250
[TBL] [Abstract][Full Text] [Related]
56. Rituximab induction therapy in highly sensitized kidney transplant recipients.
Yin H; Wan H; Hu XP; Li XB; Wang W; Liu H; Ren L; Zhang XD
Chin Med J (Engl); 2011 Jul; 124(13):1928-32. PubMed ID: 22088448
[TBL] [Abstract][Full Text] [Related]
57. Heart transplant graft survival is improved after a reduction in panel reactive antibody activity.
Schaffer JM; Singh SK; Reitz BA; Oyer PE; Robbins RC; Mallidi HR
J Thorac Cardiovasc Surg; 2013 Feb; 145(2):555-64; discussion 564-5. PubMed ID: 23246047
[TBL] [Abstract][Full Text] [Related]
58. Successful transplantation across positive B-cell cross-match in deceased donor renal transplants.
Goh A; Oei E; Vathsala A
Transplant Proc; 2012 Jan; 44(1):193-9. PubMed ID: 22310613
[TBL] [Abstract][Full Text] [Related]
59. Outcomes of renal patients from the Ivory Coast transplanted abroad: time for a local kidney transplantation program.
Ackoundou-N'Guessan C; Gnionsahe DA; Dekou AH; Tia WM; Guei CM; Moudachirou AM
Transplant Proc; 2010 Nov; 42(9):3517-20. PubMed ID: 21094807
[TBL] [Abstract][Full Text] [Related]
60. Effect of Interleukin-2 Receptor Antibody Induction Therapy on Survival in Renal Transplant Patients Receiving Tacrolimus.
Ali H; Sharma A; Halawa A
Am J Nephrol; 2020; 51(5):366-372. PubMed ID: 32268334
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
